The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review
Panagiotis Filis, Ioannis Zerdes, Theodora Soumala, Alexios Matikas, Theodoros Foukakis
Abstract
The advent of targeted therapies signaled novel avenues for more optimal oncological outcomes. Antibody-drug conjugates (ADCs) have risen as a cornerstone of the ever-expanding targeted therapy era. The purpose of this systematic review is to delineate the rapidly evolving clinical landscape of ADCs for solid tumors. A literature search was performed in Medline, Embase and Cochrane databases for phase II and III clinical trials. Outcomes of interest were the objective response rate, overall survival, progression-free survival and adverse events. A total of 92 clinical trials (76 phase II and 16 phase III) evaluated the efficacy and safety of ADCs for a plethora of solid tumors. Out of the 30 investigated ADCs, 8 have received approval by regulatory organizations for solid tumors. Currently, 52 phase III clinical trials for ADCs are ongoing. ADCs have shown promising results for several solid tumors and various cancer settings. • The introduction and continuous refinement of ADCs are transforming clinical practice in oncology. • Currently 8 ADCs have received regulatory approval for use in solid tumors. • 92 phase II and III trials have evaluated the use of several ADCs in solid tumors. • The results from over 50 ongoing phase III clinical trials are eagerly awaited.